Moleculin Biotech (MBRX) Revenue & Revenue Breakdown
Moleculin Biotech Revenue Highlights
Moleculin Biotech Revenue by Period
Moleculin Biotech Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | - |
Moleculin Biotech generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Moleculin Biotech Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $406.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Moleculin Biotech generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Moleculin Biotech Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| CAPR | Capricor Therapeutics | $25.18M | $3.97M |
| PULM | Pulmatrix | $7.30M | $1.55M |
| CBIO | Gyre Therapeutics | $794.00K | - |
| CYCC | Cyclacel Pharmaceuticals | $420.00K | $4.00 |
| IKT | Inhibikase Therapeutics | $260.50K | - |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| ANTX | AN2 Therapeutics | - | - |
| BPTH | Bio-Path | - | - |
| MBRX | Moleculin Biotech | - | - |
| NXTC | NextCure | - | - |
| AKTX | Akari Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| ATXI | Avenue Therapeutics | - | - |
| CFRX | ContraFect | - | - |
| ALLR | Allarity Therapeutics | - | - |
| DFFN | CervoMed | - | - |
MBRX Revenue FAQ
What is Moleculin Biotech’s yearly revenue?
Moleculin Biotech's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. MBRX's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Moleculin Biotech’s quarterly revenue?
Moleculin Biotech's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). MBRX's quarterly revenue for Q4 2023 was $406K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Moleculin Biotech’s revenue growth rate?
Moleculin Biotech's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.